Revenue Update on Sucampo Pharmaceuticals(NASDAQ:SCMP)

Sucampo Pharmaceuticals(NASDAQ:SCMP) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 3, 2016. Company reported revenue of $51.95M. Analysts estimated a revenue of $48.33M. Earnings per share were $0.23. Analysts had estimated an EPS of $0.22.

Sucampo Pharmaceuticals (SCMP) shares turned negative on Fridays trading session with the shares closing down -0.16 points or -1.36% at a volume of 3,62,404. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $11.84. The peak price level was also seen at $11.84 while the days lowest was $11.52. Finally the shares closed at $11.61. The 52-week high of the shares is $29.67 while the 52-week low is $9.59. According to the latest information available, the market cap of the company is $532 M.

Several Insider Transactions has been reported to the SEC. On Nov 18, 2015, Andrew P Smith (CFO) purchased 1,605 shares at $17.03 per share price.Also, On Aug 31, 2015, Daniel P Getman (director) sold 30,000 shares at $28.14 per share price.On Apr 2, 2015, Sachiko Kuno (10% owner) sold 1,600,000 shares at $14.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Sucampo Pharmaceuticals Inc. is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal ophthalmic and oncology-based inflammatory disorders. It generates revenue from product royalties development milestone payments product sales and clinical development activities. Its operations are conducted through Sucampo AG (SAG) based in Zug Switzerland through which the Company conducts certain worldwide and European operations; Sucampo Pharma LLC based in Tokyo and Osaka Japan through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC based in Bethesda through which the Company conducts operations in North and South America and Sucampo Pharma Europe Ltd. based in Oxford United Kingdom. The Company’s geographic segments are Asia the Americas and Europe.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Sucampo Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Sucampo Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.